(Total Views: 449)
Posted On: 03/23/2025 11:37:11 AM
Post# of 155801
I don't recall this being posted, so I apologize if it has. CytoDyn has updated it FAQ web page.
https://www.cytodyn.com/investors/investor-faqs
Here is the first two FAQs for quick reference:
FREQUENTLY ASKED QUESTIONS
Last updated March 2025
What are the 2025 clinical objectives of the Company?
i. Continue the pending Phase II trial of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer;
ii. Conduct additional studies exploring leronlimab and its therapeutic potential in other solid-tumor oncology indications, including but not limited to metastatic Triple-Negative Breast Cancer; and
iii. Continue our work researching and developing a new or modified long-acting version of leronlimab.
The Company will also strategically work with select partners to explore leronlimab’s potential benefits in certain inflammatory diseases.
What is the current status of the longer-acting therapeutic project?
In order to develop a long-acting therapeutic, we have partnered with an experienced drug development company that uses generative artificial intelligence (AI), among other technologies, in its development activities. If successful, such a modified therapeutic would require less frequent injections for patients on drug, furthering the convenience and overall marketability of the product. Working with a company with established AI-capabilities allows for a robust development path for this modified, longer-acting therapeutic for the Company. This joint development initiative remains in progress at this time and the Company will provide further updates when appropriate.
https://www.cytodyn.com/investors/investor-faqs
Here is the first two FAQs for quick reference:
FREQUENTLY ASKED QUESTIONS
Last updated March 2025
What are the 2025 clinical objectives of the Company?
i. Continue the pending Phase II trial of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer;
ii. Conduct additional studies exploring leronlimab and its therapeutic potential in other solid-tumor oncology indications, including but not limited to metastatic Triple-Negative Breast Cancer; and
iii. Continue our work researching and developing a new or modified long-acting version of leronlimab.
The Company will also strategically work with select partners to explore leronlimab’s potential benefits in certain inflammatory diseases.
What is the current status of the longer-acting therapeutic project?
In order to develop a long-acting therapeutic, we have partnered with an experienced drug development company that uses generative artificial intelligence (AI), among other technologies, in its development activities. If successful, such a modified therapeutic would require less frequent injections for patients on drug, furthering the convenience and overall marketability of the product. Working with a company with established AI-capabilities allows for a robust development path for this modified, longer-acting therapeutic for the Company. This joint development initiative remains in progress at this time and the Company will provide further updates when appropriate.
(7)
(0)
